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One Sentence Summary:  
We have constructed a series of antimicrobial agents called Avidocin-CDs that 
specifically bind to the highly polymorphic S-layer and kill C. difficile; rare escape mutants 
lacked Surface layer protein A (SlpA) and exhibited severe phenotypic defects that fully 
compromised virulence without affecting colonization of the hamster gut. 
 
Abstract: 
Avidocin-CDs are a new class of precision bactericidal agents that do not damage resident gut 
microbiota and are unlikely to promote the spread of antibiotic resistance. The precision killing 
properties result from the fusion of bacteriophage receptor binding proteins (RBPs) to a lethal 
contractile scaffold from an R-type bacteriocin. We recently described the prototypic Avidocin-
CD, Av-CD291.2, that specifically kills C. difficile ribotype 027 strains and prevents 
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colonization of mice. We have since selected two rare Av-CD291.2 resistant mutants of strain 
R20291 (RT027; S-layer cassette type-4, SCLT-4). These mutants have distinct point mutations 
in the slpA gene that result in an S-layer null phenotype. Reversion of the mutations to wild-type 
restored normal SLCT-4 S-layer formation and Av-CD291.2 sensitivity; however, 
complementation with other SCLT alleles did not restore Av-CD291.2 sensitivity despite 
restoring S-layer formation. Using newly identified phage RBPs, we constructed a panel of new 
Avidocin-CDs that kill C. difficile isolates in an SLCT-dependent manner, confirming the S-
layer as the receptor in every case. In addition to bacteriophage adsorption, characterization of 
the S-layer null mutant also uncovered important roles for SlpA in sporulation, resistance to 
lysozyme and LL-37, and toxin production. Surprisingly, the S-layer-null mutant was found to 
persist in the hamster gut despite its completely attenuated virulence. Avidocin-CDs have 
significant therapeutic potential for the treatment and prevention of C. difficile Infection (CDI) 
given their exquisite specificity for the pathogen. Furthermore, the emergence of resistance 
forces mutants to trade virulence for continued viability and, therefore, greatly reduce their 
potential clinical impact. 
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Introduction 
New antibacterial agents are needed to counteract the impending loss of effective treatment 
options for multi-drug resistant bacteria. Furthering this need is the realization that dysbiosis 
caused by broad-spectrum antibiotic use contributes to the prevalence of diseases/disorders such 
as inflammatory bowel disease, obesity and gastrointestinal infections (1). Strategies to 
overcome these threats include use of narrow spectrum or precision agents and the design of 
drugs that target virulence instead of in vitro viability (2, 3). One pathogen for which alternative 
treatment approaches are needed is C. difficile. This spore-forming, obligate anaerobe is the 
leading cause of nosocomial infections worldwide. Approximately 450,000 cases and 29,000 
deaths each year are attributed to this pathogen in the US alone (4). As a result, the Centers for 
Disease Control and Prevention has identified C. difficile as an urgent threat to human health (5). 
This opportunistic pathogen exploits a reduction in gut microbiota diversity that often follows 
broad spectrum antibiotic use to proliferate, release toxins, and cause life-threatening colitis (6). 
Although the toxins have been studied in great detail, other aspects of C. difficile virulence, 
including colonization of the gut, are not well understood (6). The C. difficile cell surface is 
covered by a paracrystalline surface layer (S-layer) largely comprised of SlpA and sparsely 
interspersed by 28 related cell wall proteins (7). The S-layer precursor SlpA is proteolytically 
processed on the cell surface to generate the Low and High Molecular Weight S-layer Proteins 
(LMW and HMW SLPs). The SLPs interact with high-affinity to form a heterodimer, the basic 
unit of the mature S-layer (8). The slpA gene is located within a highly variable S-layer cassette 
consisting of 5 genes; 13 distinct S-layer cassette types (SLCTs) have been described to date (9). 
The variation that defines individual cassette types is largely confined to the LMW SLP-
encoding region of slpA (4). The HMW SLP region is highly conserved and includes the cell 
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wall binding motifs that anchor the S-layer to the cell wall (10). The S-layer and several 
associated cell wall proteins have been implicated in colonization of host tissues (7) and in 
stimulation of the host immune response via TLR4 signaling (11).  
Whereas C. difficile is not significantly resistant to the frontline antibiotics used to treat CDIs 
(vancomycin, metronidazole and fidaxomicin), the use of these antibiotics causes further 
disruption of the resident microbiota leading to frequent CDI relapse (6). To be safe and 
effective, new agents to treat and prevent CDIs must not harm the diverse gut microbiota and the 
colonization resistance it provides. Avidocin-CDs represent one such potential agent (12). These 
bactericidal proteins are genetically modified versions of natural R-type bacteriocins (a.k.a. 
diffocins) produced by C. difficile to kill competing C. difficile strains (13). Diffocins resemble 
myoviridae phage tails and consist of a contractile sheath, nanotube core, baseplate and tail fiber 
structures. However, instead of delivering DNA across the bacterial membrane as does a 
bacteriophage, R-type bacteriocins function as killing machines by injecting a nanotube core 
through the bacterial cell envelope and creating a small pore that dissipates the cell’s membrane 
potential (14). Killing specificity is determined by the receptor binding proteins (RBPs) located 
at the tail fiber tips that trigger sheath contraction upon binding with a cognate receptor on the 
bacterial cell surface. Genetic replacement or fusion of the RBP gene with homologues from 
other strains or RBP sources (i.e. C. difficile bacteriophages and prophage insertions) make it 
possible to retarget killing (12, 15-17). These modified bacteriocins are known as Avidocin-CDs. 
An Avidocin-CD prototype, Av-CD291.2, constructed with a bacteriophage RBP identified 
within a prophage insertion was found to be more stable than the natural parent diffocin. Av-
CD291.2 had a modified killing spectrum that included all hypervirulent RT027 C. difficile 
strains tested, blocked C. difficile colonization in a mouse model of spore transmission and did 
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not disrupt the resident gut microbiota (12). These properties encourage the further development 
of Avidocin-CDs as oral human therapeutics.  
Here we further characterize the Av-CD291.2 mechanism of action and describe an expanded 
panel of Avidocin-CDs that cover all clinically relevant C. difficile strain types using newly 
identified bacteriophage RBPs. Rare resistant mutants were isolated in vitro under Av-CD291.2 
selection. Analysis of these mutants enabled the identification of SlpA as the cell surface 
receptor for all tested Avidocin-CDs and, by extension, the corresponding bacteriophage and 
prophage RBP-sources. We also identified previously unsuspected roles for SlpA in sporulation, 
resistance to lysozyme and the natural anti-microbial peptide LL-37, toxin production and 
virulence. Surprisingly, despite their complete attenuation of virulence, resistant mutants could 
colonize and persist in the hamster gut for the duration of a 14-day study. These findings imply 
that antimicrobial agents that force pathogens to trade virulence for continued viability would 
have clear clinical advantages should resistance emerge during treatment.   
 6 
Results  
Av-CD291.2-resistant mutants lack an S-layer 
Resistance to any antimicrobial agent can occur and be exploited to understand its mode 
of action. We isolated two spontaneous mutants of C. difficile strain R20291 (ribotype 027) that 
were resistant to killing by Av-CD291.2. These mutants appeared at a frequency of < 1 x 10-9 
and were found to encode independent point mutations in the slpA gene (Fig. 1A). Both 
mutations were predicted to truncate SlpA at a site N-terminal to the post-translational cleavage 
site and, thereby, prevent formation of an S-layer. Both FM2.5 and FM2.6 lacked detectable cell 
surface S-layer protein subunits as predicted but still expressed minor cell wall proteins 
including Cwp2 and Cwp6 (Fig. 1B). These mutations did not affect the growth rate of the 
bacteria in vitro (Fig. S4B); however, FM2.5 displayed a slight, but statistically significant 
earlier entry into stationary phase (maximum OD600nm: FM2.5 = 2.2; R20291 = 3.2, p = 
0.000012). We attempted to complement the FM2.5 and FM2.6 mutations with a plasmid-borne 
wild-type R20291 slpA; however, unexpected homologous recombination restored the wild type 
slpA gene to the chromosome (Fig. S1). Accordingly, we created genetically identifiable 
recombinants “watermarked” with synonymous substitutions in the R20291 slpA allele (Fig. 1A). 
The resulting strains, FM2.5RW and FM2.6RW, were found to have LMW and HMW SLPs on 
their surface (Fig. 1B) and regained sensitivity to Av-CD291.2 (Fig. 1C and D). These results 
confirmed that an intact S-layer is required for Av-CD291.2 killing but did not determine 
whether SlpA itself or a protein dependent on the S-layer for surface localization was the 
receptor for Av-CD291.2. To address this question, slpA alleles from the most common non-
R20291 SLCTs were individually cloned into an inducible expression plasmid and transferred 
into the S-layer deficient FM2.5 (Fig. 1E). Each resulting strain expressed the expected LMW 
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and HMW SLPs on the cell surface, indicative of S-layer formation (9), but did not regain 
sensitivity to Av-CD291.2, thus, ruling out the possibility that the simple formation of an S-layer 
was responsible for sensitivity to Av-CD291.2. To address whether Av-CD291.2 directly 
interacts with SLCT-4 SlpA, plasmids encoding SlpA from 8 different SLCTs were introduced 
into the non-isogenic laboratory strain 630 (SLCT-7; ribotype 012), which is insensitive to Av-
CD291.2 (Table S1). In this fully S-layer competent SLCT-7 wild type strain, only induction of 
SLCT-4 SlpA was sufficient to confer sensitivity to Av-CD291.2 (Fig. S3). Moreover, the degree 
of sensitivity was dependent on the level of induction with only 10 ng/mL of inducer required 
(Fig. S3A). Taken together these observations clearly demonstrate that the SLCT-4 variant of 
SlpA is the cell surface target of Av-CD291.2. 
Sensitivity to all Avidocin-CDs is slpA allele-specific 
These observations suggested that each variant of SlpA may serve as a specific receptor 
for additional C. difficile bacteriophage RBPs. In an attempt to expand Avidocin-CD coverage 
beyond SLCT-4, we constructed ten new Avidocin-CDs using predicted bacteriophage RBPs 
mined from the genome sequences of C. difficile clinical isolates or newly isolated 
bacteriophages (Table S1). Source strains for RBP sequences were chosen based on their SLCT 
since strain typing information for the RBP source often correlates with sensitivity to the 
corresponding Avidocin (e.g. ribotype 027 and sensitivity to Av-CD291.2; SLCT-1 of phi-147 
propagating strain and sensitivity to Av-CD147.1) (12, 15, 16). Preparations of Diffocin-4 
(scaffold for all Avidocin-CDs), Av-CD291.2, and each of the new Avidocin-CDs were tested 
for killing activity on a panel of 62 C. difficile isolates containing all 13 known SLCTs and a 
newly identified 14th SLCT (Fig. S2). Only two strains, representing SLCTs 3 and 5, were not 
killed by a single Avidocin-CD (Fig S2); otherwise, every isolate from all 12 other SLCTs was 
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killed by at least one Avidocin-CD. A near perfect correlation was observed between a strain’s 
SLCT and its sensitivity to each of the Avidocin-CDs. The only exceptions were SLCT-2 
isolates with Av-CD027.2 and Av-CD685.1. A strong correlation was also observed between 
ribotype and sensitivity to a particular Avidocin-CD since all ribotypes in the panel, except 012, 
014 and 015, were found to associate exclusively with a single SLCT. Similar correlations with 
strain sensitivity and SLCT or ribotype were not observed for killing with Diffocin-4, suggesting 
this natural R-type bacteriocin binds to C. difficile via another receptor. 
Having made these observations, we wanted to determine if sensitivity to specific 
Avidocin-CDs was directly dependent upon the variant of SlpA present. The panel of isogenic 
FM2.5 strains complemented with slpA alleles from the 10 most common SLCTs was tested for 
sensitivity to a panel of the most potent Avidocin-CDs (Fig. 2). The corresponding parental 
strains from which the slpA alleles were obtained were used as controls. Each complemented 
strain became sensitive to the same Avidocin-CDs as the parental strain. To confirm that this 
engineered sensitivity did not result from altered cell surface architecture, an analogous 
experiment was performed in a second panel of isogenic strains created when plasmids encoding 
SlpAs from 8 SLCTs were introduced into the S-layer competent strain 630 (Fig. S3B and C). As 
before, the spectrum of killing was identical to that of the parental strains from which the slpA 
alleles were obtained. These data conclusively demonstrate that the polymorphic SlpA acts as the 
binding receptor for each of the Avidocin-CDs tested and, therefore, the corresponding 
bacteriophage RBPs. 
S-layer null mutants are abnormally sensitive to innate immune effectors 
Bacterial S-layers serve many critical cellular functions (7). Given its location on the cell 
surface, the S-layer has been proposed to act as a molecular sieve to selectively limit exposure of 
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the underlying cell envelope to large biomolecules such as the innate immune effector lysozyme 
(18). Until now, analysis of C. difficile S-layer function has been hampered by an inability to 
isolate slpA-deficient mutants (19). While C. difficile is highly resistant to killing by this enzyme, 
resistance has been attributed to extensive peptidoglycan deacetylation (20). To determine if the 
S-layer also plays a role in lysozyme resistance, we treated exponentially growing bacteria with a 
high concentration of lysozyme (500 µg/ml) and monitored the effects on growth (Fig. 3A). 
Upon addition of lysozyme an immediate decrease in optical density consistent with cell lysis, 
followed by slower growth, was observed for the S-layer mutant FM2.5. In contrast, R20291 and 
FM2.5RW displayed only a transient decrease in growth rate, consistent with natural resistance. 
Having confirmed a role for the S-layer in lysozyme resistance, we then tested for resistance to 
the human cathelicidin antimicrobial peptide LL-37 to determine if S-layer-mediated resistance 
extended to other innate immune effectors (Fig. 3B). LL-37 is found at mucosal surfaces at 
concentrations of up to 5 µg/ml in normal conditions with further expression induced in response 
to infection (21). Treatment with 5 µg/ml of LL-37 completely killed exponentially growing 
cultures of the S-layer mutant FM2.5; whereas, the same treatment caused only a slight reduction 
in growth rates for R20291 and FM2.5RW. Taken together, these data demonstrate a role for the 
S-layer in resistance to both lysozyme and LL-37.  
S-layer null mutants display severe sporulation defects 
It was noted that the S-layer mutant strains survived poorly in the standard charcoal 
medium used to transport C. difficile strains. The ability of C. difficile to survive in the 
environment and be transmitted to new hosts is reliant on the bacterium’s ability to produce a 
heat and chemical-resistant spore (22). We analyzed sporulation efficiency by measuring the 
numbers of heat-resistant spores as a percentage of total viable CFUs over 5 days (Fig. S4A). 
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Spore production by wild type R20291 and FM2.5RW cultures was reproducible and equivalent 
and represented 73 and 85% of total viable counts on day 5, respectively (Fig. 3C). In contrast, 
spore production by FM2.5 was significantly lower (p = <0.00001). Spores only represented 
4.3% of total viable counts on day 5, which is a 17-20-fold reduction compared to R20291 and 
FM2.5RW. These observed differences in FM2.5 spore formation were not due to an inability to 
germinate efficiently (Fig. 3D). When the bile salt germinant taurocholate was added to purified 
spore preparations, the speed and efficiency of germination initiation for FM2.5 spores was 
indistinguishable from that of R20291 and FM2.5RW. Analysis of bacterial cultures by phase 
contrast microscopy also pointed to a reduction in sporulation efficiency (Fig. S4C and D), as 
5.2-fold fewer phase bright spores were observed in cultures of FM2.5 (FM2.5, 8.7% vs R20291, 
44.9%; FM2.5RW, 45.4%). Interestingly, we noted a discrepancy between the magnitudes of the 
sporulation defect determined microscopically (5.2-fold less than R20291) compared with direct 
counting of viable spore CFUs (20-fold less than R20291). This suggests that many of the 
microscopically counted spores were nonviable following the 65°C heat treatment required to 
differentiate spores from vegetative cell CFUs. To test the FM2.5 spores for possible stress 
resistance defects, we exposed the cultures to a harsher heat treatment (75°C for 30 min). The 
75°C heat treatment further reduced FM2.5 spore viability 33-fold compared with the standard 
65°C (Fig. 3C). The same treatment only reduced spore viability by 1.5-fold for R20291 and 2-
fold for FM2.5RW. Collectively, these data indicate that the production and quality of the 
infectious spores are severely impaired by the loss of the S-layer.  
Transmission electron microscopy was employed to identify potential morphological 
changes associated with these defects (Fig. S5). In FM2.5 cultures we observed spores with 
disorganized material loosely attached to the electron-dense core that lacked discernible, well-
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organized protein coat layers (23)(Fig. S5A). To determine if these unusual spore morphologies 
were responsible for the observed thermal sensitivity, we repeated these analyses with spores 
purified on a Histodenz gradient. Following purification, spores of FM2.5 were morphologically 
indistinguishable from those of R20291 and FM2.5RW (Fig. S5C). Surprisingly, purified FM2.5 
spores still displayed increased thermal sensitivity. A75°C heat treatment reduced FM2.5 spore 
viability 37.1-fold compared to 10- and 18.1-fold for R20291 and FM2.5RW respectively (Fig. 
S5B). Several distinct biochemical and structural features of the spore, including the concentric 
cortex peptidoglycan and protein layers and core dehydration, have been independently linked to 
heat resistance (24-26). Minor defects in any of these features could explain the observed 
thermal sensitivity of FM2.5 spores. 
S-layer null mutants are completely avirulent despite persistent gut colonization 
We tested the ability of the S-layer mutant FM2.5 to cause disease in the Golden Syrian 
hamster model of acute CDI. As expected, all animals inoculated with FM2.5RW behaved 
similarly to animals inoculated with the wild type R20291 strain and succumbed to C. difficile 
infection within 102 h of infection, with mean times to cull for R20291 and FM2.5RW of 67 h 
36 min and 57 h 19 min, respectively (p = 0.52, Fig. 4A). Both groups of hamsters showed 
typical signs of disease including wet tail and drop in body temperature at experimental 
endpoint. In contrast, all animals inoculated with FM2.5 displayed no signs of disease and 
survived for the duration of the 14-day study (p = 0.0018; FM2.5 vs R20291, Fig. 4A). Very few 
described mutations located outside of the PaLoc locus have resulted in complete avirulence in 
this model (27). Surprisingly, the lack of virulence was not due to a colonization defect. FM2.5 
was capable of persistent colonization; CFUs in the caecum and colon at the end of study (14 
days) were not statistically different to those observed for R20291 and FM2.5RW in the same 
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tissues taken at experimental endpoint some 10 days earlier (Fig. 4B). Toxin measurements from 
gut contents 14 days after inoculation with FM2.5 showed dramatic reductions in both toxin A or 
B activity compared to samples taken from hamsters that succumbed to infection with either the 
R20291or FM2.5RW (Fig. 4C and 4D). 
S-layer null mutants lack toxin production in vitro 
Given the avirulence and low toxin activity observed in animals, we assayed the FM2.5 
and control strains for toxin production in vitro (Fig. 4E). Toxin B was used as an indicator for 
both toxins since they are coordinately expressed and released (6). As expected, both R20291 
and FM2.5RW produced toxin upon entry into stationary phase. A small amount of Toxin B was 
detected intracellularly at 24 hours; thereafter, Toxin B was exclusively detected in the culture 
supernatant. Cultures of FM2.5 produced less Toxin B at all time-points, consistent with in vivo 
observations. 
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Discussion  
The bactericidal properties of Avidocin-CDs bode well for the clinical application of this 
new class of antimicrobial agents for combating CDI. Previous studies demonstrated that killing 
by the prototypic Avidocin-CD, Av-CD291.2, was highly specific for BI/NAP1/027-type strains 
and did not detectably alter the resident gut microbiota in mice (12). For production purposes 
fermentation of genetically modified B. subtilis expressing these agents is similar to many 
established industrial processes and scalable to thousands of liters. We selected, isolated and 
characterized rare C. difficile mutants resistant to Av-CD291.2 to better understand its 
mechanism of action. In the process we discovered the Avidocin-CD binding receptor, the C. 
difficile S-layer protein SlpA. Indeed, our 10 new Avidocin-CDs were all found to target variants 
of SlpA associated with different SLCTs. Given that the great majority of the sequence variation 
in SlpA is found within the surface exposed LMW subunit (9), this relationship between SLCT 
and Avidocin-CD sensitivity strongly suggests that the LMW SLP is the binding site for all the 
studied Avidocin-CDs. Further, it indirectly identifies this portion of the SlpA as the binding 
receptor for many C. difficile myophages since each Avidocin-CDs is constructed with a 
different bacteriophage-derived RBP. These findings help explain the limited host ranges 
observed for many C. difficile myophages (28, 29). It also suggests that antigenic variation 
observed between SLCTs may not be due to immune escape as previously proposed (9) but 
rather due to a molecular arms race between bacteria and bacteriophages. C. difficile is under 
selective pressure to change the bacteriophage receptor, which in turn puts selective pressure on 
the bacteriophages to evolve new RBPs.  
 Interestingly, patterns of strain sensitivity to each Avidocin-CD indicate killing was 
much broader than the parental bacteriophage’s host range (Fig. S2 and S7). A possible 
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explanation for this observation is that a typical bacteriophage infection cycle is a 7-step process: 
attachment, genome injection, replication, transcription, translation, assembly and lysis. Bacteria 
can become resistant to a bacteriophage by blocking any stage of the infection cycle. For 
example, CRISPR-Cas or restriction-modification systems that prevent phage DNA from 
replicating (30). In contrast, Avidocin-CD killing is a 2-step process: attachment to the target 
bacterium followed by killing via creation of a small pore that dissipates the target bacterium’s 
membrane potential, importantly, without lysis or release of macromolecules such as exotoxin 
from the cytoplasm (Fig. S6). As observed with other Avidocins and R-type bacteriocins (16, 
31), selected Avidocin-CD resistant mutants survived due to mutations that caused the loss or 
modification of the SlpA binding receptor and not due to mutations that directly disrupted the 
killing mechanism, such as improper pore formation, or caused proteolytic cleavage of the agent. 
The bias towards receptor mutations suggests the Avidocin-CD killing mechanism is simple and 
robust.  
Modification of the binding receptor to avoid Avidocin-CD killing either through 
missense mutations or S-layer switching, as evidenced by the random association between clades 
and SLCTs (9), could also theoretically lead to resistance. While sequence variations between 
slpA alleles within each SLCT indicate missense mutations do occur (9), our findings suggest 
resistance due to this type of modification is unlikely since the bacteriophage RBPs used to 
construct the Avidocin-CDs have already evolved to counter this mode of potential escape. For 
instance, both Av-CD684.1 and Av-CD685.1 kill every SLCT-7 strain tested despite sequence 
identities between SLCT-7 SlpAs as low as 81% (Fig. S8). As for the emergence of resistance 
via horizontal transfer of the S-layer cassette, the administration of a cocktail of Avidocin-CDs 
that kill all the common SLCTs would make successful resistance via S-layer switching 
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extremely unlikely. It appears that the only likely means of resistance to all the Avidocin-CDs is 
through complete loss of SlpA, as observed for resistance to Av-CD291.2. As a consequence the 
observed phenotypes for FM2.5 are germane to all likely Avidocin-CD-resistant mutants. 
For a precision medicine agent to be successful, knowing the molecular target, in this 
case the binding receptor, is vital in designing accurate diagnostics to guide treatment decisions. 
If Avidocin-CDs were to be administered individually, a diagnostic determining SLCT of 
infecting C. difficile would be highly accurate for informing Avidocin-CD treatment decisions. 
However, an increase in the prevalence of hybrid cassettes, as found in ribotype 078 strains (9), 
would decrease the accuracy for this typing method. Strain ribotyping could also be employed to 
avoid development of new diagnostics, but predicting sensitivity to a particular Avidocin-CD 
may be challenging as ribotypes are not consistently linked to a single SLCT (i.e. 012, 014, and 
015, as noted above). SlpA-typing would provide the most accurate diagnostic as well as prove 
more illuminating than ribotyping since SlpA is directly related to the physiology of C. difficile, 
whereas, ribotyping detects physiologically inconsequential ribosomal RNA gene 
polymorphisms. It may also be possible to administer a cocktail of 5-6 Avidocin-CDs that target 
12 of the 14 C. difficile SLCTs. If such a cocktail of Avidocin-CDs were to be administered, a 
point of care diagnostic would only need to detect the presence of C. difficile to guide treatment 
decisions. 
The strong selective pressure afforded by Av-CD291.2 allowed isolation of the first 
spontaneous C. difficile S-layer null mutants. In addition to enabling identification of the 
Avidocin-CD cell surface receptor, these mutants also provide an unprecedented opportunity to 
study S-layer function (Fig. 5). Given the ubiquity of S-layers in both Bacteria and Archaea, 
including many pathogenic species, surprisingly little is known about their function. It has been 
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suggested that the S-layer could act as a molecular sieve to exclude certain large biomolecules 
from the cell envelope (18); however, this has not been confirmed in live cells. We have 
demonstrated that an intact S-layer is required for resistance to two components of the innate 
immunity system, lysozyme and the antimicrobial peptide LL-37. Assembled S-layers are highly 
symmetrical with regular repeating pores. The size of the pores in the C. difficile S-layer is not 
yet known but in other species pore sizes of between 2 and 6 nm have been reported. A pore size 
of 2 nm could conceivably exclude the16 kDa globular protein lysozyme but a small peptide 
such as LL-37 would experience no such steric hindrance. It is possible that charged surfaces on 
the assembled S-layer serve to sequester the cationic peptide away from the cell envelope in a 
manner analogous to capsular polysaccharides (32). Our data has identified other pleiotropic 
functions for the C. difficile S-layer. It is clear that the S-layer is the cell surface receptor for all 
of the Avidocin-CDs described here and, by extension, the receptor for the bacteriophages from 
which the RBP-encoding genes were cloned. Although a Bacillus bacteriophage has been found 
to bind S-layer protein Sap (33), this is the first time a receptor for a C. difficile bacteriophage 
has been identified. Furthermore, our data imply that S-layer recognition is a common feature of 
bacteriophages that infect this species. 
Surprisingly, the S-layer mutant also displayed severe sporulation defects, with fewer and 
morphologically defective spores produced. Despite a number of well-studied spore-forming 
organisms producing S-layers, including B. anthracis (33), S-layer biogenesis has not been 
reported previously to affect sporulation. There is currently no evidence to suggest that the SLPs 
are a structural part of the mature spore and the mechanisms by which the S-layer can influence 
sporulation are currently unknown. However, this observation has serious ramifications for the 
ability of an Avidocin-CD-resistant, S-layer defective mutant to survive and be transmitted to 
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other hosts. The spore is an absolute requirement for C. difficile survival in the aerobic 
environment and is critical for transmission (22). In addition to sporulation defects, the S-layer 
mutant was also found to produce less toxin in vitro. Interestingly, there have been previous 
suggestions of feedback between sporulation and the complex regulatory network controlling 
toxin production (22). Although the mechanism by which these processes are affected in SlpA 
null mutants is far from clear, it is possible that the S-layer feeds into a point of crosstalk 
between regulation of virulence and transmission. Given the poor toxin production and other 
diverse phenotypes identified for the S-layer mutant, it is probably not surprising that the mutant 
was entirely avirulent in the hamster model of acute infection. What did come as a surprise, 
however, was the ability of the S-layer mutant to stably colonize and persist in the hamster gut 
for the 14-day duration of the experiment. Previous reports have pointed to a role for the S-layer 
in epithelial cell adhesion; however, these earlier studies were performed without access to an 
slpA-defective strain (34). The S-layer defective mutants and isogenic controls expressing the 
SLCT-specific slpA alleles provide the ideal controls to test these conflicting findings and better 
define the effect SlpA type has on these functions. 
There are several study limitations that should be considered when evaluating the data 
presented. The activity of each new Avidocin-CD was observed in vitro and needs to be 
confirmed in an animal treatment model, as done for Av-CD291.2. Similarly, the exquisite 
specificity of each agent for distinct C. difficile SLCTs also needs be tested in vivo to confirm 
that treatment with these agents will not alter the diversity of the gut microbiota. The avirulent 
phenotype and long-term persistence of the Avidocin-CD-resistant slpA mutants in the hamster 
model should also be confirmed in other animal species. Finally, the implications of the mutants’ 
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observed sporulation defects on transmission and the spread of resistance remain to be tested in 
vivo. In all cases, we do not anticipate different outcomes from those described here. 
After accounting for these limitations, analysis of the data clearly demonstrates that 
acquisition of Avidocin-CD resistance results in loss of toxin production and complete loss of 
virulence. Virulence factors make attractive targets for new antimicrobials as they tend to be 
species-specific, and emergence of resistance is likely to reduce virulence. The ability of the S-
layer mutant to stably colonize the gut in the absence of clinical disease reveals that the in vivo 
lifestyle of the organism is independent of toxin production and virulence. The prevalence of 
non-toxigenic, avirulent C. difficile strains in the general population (35) supports this 
hypothesis. As a result, we predict that there will be no competing selective pressure to restore 
virulence in the context of Avidocin-CD resistance. 
 In summary, we have developed and characterized multiple new Avidocin-CDs, 
providing crucial insights into their potential advantages in the clinic. The precise killing activity 
of Avidocin-CDs makes them attractive agents for both treatment and prevention since they can 
be administered to patients without altering the diversity of the complex gut microbiota. In 
addition, when resistance does emerge, Avidocin-CDs force the pathogen to sacrifice virulence 
for viability - making the potential clinical impact of resistance inconsequential.  
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Materials and Methods 
Study design 
The objective of this study was to characterize a panel of Avidocin-CDs, anti-bacterial protein 
complexes constructed to specifically target and kill C. difficile. During these experiments, the 
isolation of Avidocin-CD resistant slpA mutants allowed detailed analysis of S-layer function for 
the first time. Starting from the prototypic Av-CD291.2 (12) we constructed a panel of new 
Avidocin-CDs using bacteriophage RBPs we identified. Each new Avidocin-CD displayed a 
unique spectrum of killing activity with a strong correlation to SLCT. Sensitization of two 
insensitive C. difficile strains by heterologous expression of a cognate SLCT SlpA alone allowed 
identification of the S-layer as the receptor for all described Avidocin-CDs. Analysis of the slpA 
mutant identified previously unsuspected in vitro roles for the S-layer in resistance to the 
immune effectors lysozyme and LL-37, and in the production of mature heat-resistant spores. 
Finally, use of the Golden Syrian hamster model of acute infection demonstrated that the slpA 
mutant was entirely avirulent despite persistent infection. Greatly reduced toxin activity was 
detected in intestinal contents from animals colonized with the slpA mutant and this observation 
was supported by identification of a toxin production defect in vitro. The design and execution of 
these animal experiments is described in detail in Supplementary Methods. 
 
Strains, bacteriophage and culture conditions. 
Bacterial strains used in this study are described in Figure S2. DNA oligonucleotides are 
described in Table S2. E. coli strains were routinely grown in LB broth and on LB agar (VWR). 
C. difficile strains were routinely grown under anaerobic conditions on BHI or BHI-S agar and in 
TY broth (36) except where otherwise stated. Cultures were supplemented with chloramphenicol 
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(15 µg/ml), thiamphenicol (15 µg/ml) or anhydrotetracycline (20 ng/ml) as required. C. difficile 
SLCTs were determined by analyzing the nucleotide sequence of the slpA gene. When necessary, 
the slpA gene was sequenced using oligonucleotide primers previously described (37, 38) or 
primers 023-F and 023_010-R or 014+++-F and 014_002+-R (nucleotide sequences - Table S2). 
The variable region of strain 19142 (ribotype 046) slpA gene did not display high sequence 
identity with other slpA alleles, and has been designated SLCT-13. A partial strain 19142 slpA 
sequence was deposited in Genbank (accession: KX610658). Details of plasmid and strain 
construction are given in Supplementary Methods. 
 
Bioassays to determine Avidocin-CD killing activity. 
Avidocin-CD bactericidal activity was assayed by a semi-quantitative spot method as previously 
described (12, 13). For broth-based killing assays, C. difficile strains were grown overnight in 
TY broth and then sub-cultured to an OD600nm of 0.05 in 1 ml fresh TY supplemented with 1mM 
CaCl2. Av-CD291.2 (50 µl) was added to each culture after 2.5 h. Growth was monitored by 
measuring the OD600nm hourly. 
 
Extraction of S-layer and associated proteins. 
S-layer proteins were extracted using low pH glycine as previously described (8) and analyzed 
by SDS-PAGE using standard methods. 
 
Quantitative analysis of sporulation and germination. 
Quantitative analysis of sporulation was carried out as previously described (19) and monitored 
by phase contrast and transmission electron microscopy as described in Supplementary Methods.  
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Analysis of resistance to lysozyme and LL-37. 
Broth based killing assays were carried out as described above but with lysozyme (500 µg/ml) or 
LL-37 (5 µg/ml) added after 2.5 h growth. Cell density was monitored by measuring the OD600nm 
hourly. Assays were carried out in triplicate on biological duplicates.  
 
Animal experiments. 
The Golden Syrian hamster model was performed as previously described (39). All procedures 
were performed in strict accordance with the Animals (Scientific Procedures) Act 1986 with 
specific approval granted by the Home Office, U.K. (PPL60/4218). Further detail is given in 
Supplementary Methods. 
 
Quantification of toxin expression. 
Quantification of toxin activity was performed using Vero cells as described previously (39) and 
by Western immunoblot using anti-Toxin B antibody. Further details are given in Supplementary 
methods. 
 
Statistical analyses. 
Data were analyzed using GraphPad Prism software (GraphPad Software Inc.). Toxin production 
was compared using a two-tailed nonparametric Mann-Whitney test, and animal survival curves 
were analyzed using a Log-rank (Mantel-Cox) test. All other statistical analyses were performed 
using two-tailed t-tests with Welch's correction.  
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Figure Legends:  
Fig. 1. Mutations in slpA confer Av-CD291.2 resistance. (A) Alignment of the slpA sequence 
(nucleotides 268-294) from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. A nucleotide 
insertion at position 283 of FM2.5 slpA results in a frameshift and premature stop codon (in 
blue). A nucleotide substitution at position 280 of FM2.6 slpA results in a nonsense mutation (in 
red). To allow differentiation from the wild type sequence, two synonymous mutations were 
introduced into slpA in FM2.5RW and FM2.6RW (in green) (B) SDS-PAGE analysis of S-layer 
extracts from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. The positions of the LMW 
and HMW SLPs and minor cell wall proteins Cwp2 and Cwp6 are indicated. (C and D) The 
impact of Av-CD291.2 on exponentially growing R20291, FM2.5, FM2.5RW and FM2.6RW 
was monitored by measuring the optical density at 600 nm. Av-D291.2 addition is indicated with 
an arrow. Experiments were carried out in triplicate on biological duplicates. Means and standard 
deviations are shown. (E) SDS-PAGE analysis and Av-CD291.2 sensitivity of FM2.5 
complemented with slpA alleles from multiple SLCTs following induction with 
anhydrotetracycline (20 ng/ml). R20291 and FM2.5RW are included as controls. A zone of 
clearance in the agar lawn indicates killing. 
 
Fig. 2. Avidocin-CD sensitivity correlates with SLCT. (A) SDS-PAGE analysis of SLPs 
extracted from a panel of strains representing the 11 most commonly isolated SLCTs. (B) Spot 
bioassays with 8 Avidocin-CDs on the C. difficile strains used in panel A, as well as FM2.5 alone 
(-) and FM2.5 complemented with slpA alleles from 10 SLCTs following induction with 
anhydrotetracycline (20 ng/ml). The zone of clearance caused by each Avidocin-CD is shown 
along with SLCT (H = Hybrid 2/6). 
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Fig. 3. Phenotypic characterization of FM2.5. (A and B) Cultures of R20291, FM2.5 and 
FM2.5RW were challenged with lysozyme (500 µg/ml; A) or LL-37 (5 µg/ml; B) in exponential 
phase after 2.5 h (indicated with arrows). Untreated control cultures were grown in parallel. 
Experiments were carried out in triplicate on biological duplicates. Means and standard 
deviations are shown. (C) Sporulation of R20291, FM2.5, and FM2.5RW after 5 days. Spore 
CFUs were determined following a standard 65°C heat treatment for 30 minutes or a harsher 
75°C heat treatment for 30 minutes. Heat-resistant spore CFUs are expressed as a percentage of 
total viable CFUs (spores and vegetative cells). Experiments were carried out in duplicate on 
biological duplicates. Mean and standard deviation are shown. * = P<0.01, determined using 
using two-tailed t-tests with Welch's correction. (D) Germination of R20291, FM2.5, and 
FM2.5RW spores. Synchronous germination of purified spores was induced with the bile salt 
taurocholate. Germination initiation was monitored by measuring the resulting decrease in 
optical density at OD600nm. 
 
Fig. 4. In vivo analysis of slpA mutant in the Syrian Golden hamster. (A) Times to experimental 
endpoint of animals infected with R20291 (black line), FM2.5 (dark blue line) and FM2.5RW 
(light blue line) respectively. Each line represents 6 animals. (B) Total CFUs and spore CFUs 
(following heat treatment at 56°C for 20 min) were determined for Lumen- (LA) and tissue-
associated (TA) bacteria recovered from caecum (CAE) and colon (COL) of infected animals 
and quantified at experimental endpoint (R20291 and FM2.5RW) or at 14 days post-infection 
(FM2.5). Shown are the mean and standard error. The horizontal dotted line indicates the limit of 
detection. None of the observed differences, including those for the TA-spore CFUs from the 
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colon, are statistically significant. (C and D) Relative toxin activity of filtered gut samples on 
HT-29 (toxin A) and Vero cells (toxin B) respectively. Values represent the reciprocal of the first 
dilution in which cell morphology was indistinguishable from untreated wells. Samples were 
taken at experimental endpoint (R20291 and FM2.5RW) or at 14 days post-infection (FM2.5). (* 
= P <0.05, ** = P <0.01, NS = not significant, determined using using a two-tailed 
nonparametric Mann-Whitney test. (E) In vitro cell lysate and culture supernatant samples from 
R20291, FM2.5 and FM2.5RW were normalized to an equivalent optical density and separated 
on 6% SDS polyacrylamide gels. Toxin B was detected by Western immunoblot using an anti-
Toxin B monoclonal antibody. Samples were taken at the indicated time points. 
 
Fig. 5. Schematic diagram depicting the phenotypes of Wild Type (A) and S-layer null mutant 
(B) cells in C. difficile biology and pathophysiology. Processes labeled in black indicate new 
functions discerned in this manuscript. Processes labeled in grey indicate previously identified 
functions. Dotted lines indicate relationships that need to be studied further. Question marks 
indicate previously described connections incompatible with observations made with the S-layer 
null mutant and warranting further investigation. (C) Schematic of Avidocin-CD structure and 
function. Binding to C. difficile by the Avidocin-CD receptor binding proteins (RBPs) triggers 
the sheath to contract and force the hollow nanotube core across the cell envelope. The resulting 
pore allows small metabolites, such as protons, ATP and cations, to escape from the cell 
cytoplasm, which, in turn, disrupts the cell’s membrane potential and kills the cell. 
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SUPPLEMENTAL MATERIALS 
 
Material and Methods 
Cloning of slpA alleles and construction of revertants. 
The slpA genes from a panel of C. difficile strains with distinct SLCTs were amplified using the 
primers listed in Table S2 and cloned between BamHI and SacI sites in the inducible expression 
plasmid pRPF185 (40). Plasmids were transferred into C. difficile strain FM2.5 by conjugation 
from the E. coli donor CA434. For construction of slpA revertants, a watermark consisting of two 
adjacent synonymous mutations, was introduced into the SLCT-4 slpA using primers RF135 and 
RF136. Single crossover recombinant colonies were identified by an enhanced growth 
phenotype, and recombination was confirmed by PCR using primers RF33 and NF1323. Stable 
double crossover revertants were isolated following growth without selection for approximately 
20 generations and confirmed by screening for plasmid loss, sequencing of the slpA gene, and 
confirmation of SLP expression by SDS-PAGE analysis (described below). 
 
Construction and expression of Avidocin-CDs. 
New Avidocin-CDs were constructed with bacteriophage RBPs identified from newly isolated 
bacteriophages and prophage insertions. The RBP genes along with the adjacent 3’end of the 
Baseplate attachment region (Bpar) and chaperone genes were cloned and inserted into an 
integration vector containing the Diffocin-4 gene cluster via a combination of restriction enzyme 
digests and Gibson assembly. The fusion sites used to replace the bacteriocin genes and integrate 
the bacteriophage derived genes are shown (Fig. S9). Avidocin constructs using the downstream 
fusion site 1 are denoted with a “.1” suffix (i.e. Av-CD681.1), while constructs using the 
downstream fusion site 2 are denoted with a “.2” (i.e. Av-CD027.2). The resulting integration 
vectors were sequence verified and transformed into the B. subtilis production strain as 
previously described (12). The nucleotide sequences for the Bpar fusion, RBP and downstream 
chaperones have been deposited in Genbank along with source information. Accession numbers 
are provided in Table S3. Expression of each Avidocin-CD was induced with IPTG as previously 
 2 
described (12). Preparation of each Avidocin-CD and Diffocin-4 relied on a combination of 
Polyethlene-glycol-8000 precipitations and ultracentrifugation as described previously (12). 
 
Isolation of Av-CD291.2-resistant clones. 
A greater than 100-fold excess of active Av-CD291.2 was added to exponentially growing C. 
difficile strain R20291. After 75 min bacteria were harvested, resuspended in phosphate buffered 
saline (PBS), and spread on non-selective Brucella agar plates maintained under anaerobic 
conditions at 37°C overnight. CFU counts before and after addition of Av-CD291.2 were 
compared to determine resistance frequency. Resistant colonies were streaked on C. difficile-
selective agar and Av-CD291.2-resistance was confirmed. Av-CD291.2-resistant strains FM2.5 
and FM2.6 was sequenced by Illumina Miseq and identified slpA mutations were confirmed by 
Sanger sequencing. 
 
Quantitative analysis of sporulation and germination. 
Overnight bacterial cultures were diluted to 0.01 OD600nm in BHI-S broth, incubated for 8 hours, 
diluted again to 0.0001 OD600nm and grown overnight. The resulting stationary phase cultures 
(T=0) were then incubated for 5 days. The relative proportion of spores and vegetative cells was 
determined at 24 h intervals by counting total and heat-resistant (65°C for 30 min) CFUs on 
BHI-S agar supplemented with 0.1 % taurocholate. Assays were repeated in triplicate with 
biological triplicates. In order to test a range of different stress conditions, additional samples 
were taken on day 5 and treated at either 75°C for 30 min, 50% ethanol for 30 min or incubated 
aerobically for 18 h before enumerating viable spores as before. For the germination studies, 
spores were purified as previously described (19) and Ca2+-DPA release and core rehydration 
was monitored by measuring changes in OD600nm upon addition of 0.5% taurocholate. 
For microscopic examination, bacterial samples were washed with PBS and fixed in 3.2% 
paraformaldehyde. For phase contrast microscopy, samples were mounted in 80% glycerol and 
visualised using a Nikon Ti Eclipse inverted microscope. For TEM, samples were additionally 
fixed in 3% glutaraldehyde in 0.1 M cacodylate buffer followed by 1% OsO4, then dehydrated in 
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ethanol and embedded in araldite resin. Embedded samples were sectioned at 85 nm on a Leica 
UC6 ultramicrotome, transferred onto coated copper grids, stained with uranyl acetate and lead 
citrate and visualized using a FEI Tecnai BioTWIN TEM at 80 kV fitted with a Gatan 
MS600CW camera. 
 
Animal experiments. 
All procedures were performed in strict accordance with the Animals (Scientific Procedures) Act 
1986 with specific approval granted by the Home Office, U.K. (PPL60/4218) for the experiments 
outlined. Briefly, 3 weeks before bacterial challenge, telemetry chips were surgically inserted by 
laparotomy into the peritoneal cavity of female Golden Syrian hamsters. Animals were allowed 
to recover from surgery before being placed in cages above transponder receiver plates that allow 
direct monitoring of body temperature. All animals were orally dosed with clindamycin 
phosphate (30 mg/kg) five days prior to challenge with 104 spores of either C. difficile R20291, 
FM2.5 or FM2.5RW as previously described (39). Six animals per group were inoculated and 
animals monitored carefully for onset of symptoms. Animals were culled when core body 
temperature dropped below 35°C. 
To quantify colonization at experimental endpoint, the caecum (CAE) and colon (COL) of each 
animal were removed, opened longitudinally and washed thoroughly in PBS to remove unbound 
bacteria; these organisms were designated luminal associated organisms (LA). The washed tissue 
was then homogenized and subsequently recovered material contained more intimately 
associated organisms; designated tissue associated (TA). Total viable counts were determined by 
plating serial dilutions on ChromID (Biomeuriex). Spores were enumerated following heat-
treatment at 56°C for 20 min. Colonies from all plates were subjected to PCR amplification of 
both the slpA gene specifically, using primers RF110 and RF111, and seven repeat regions to 
confirm strain identity by MVLA analysis 2 to confirm strain identity. 
 
Quantification of toxin expression. 
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Quantification of toxin activity was performed using a Vero cell based cytotoxicity assay. 
Dilutions of filtered (0.45 µm) post-challenge gut contents were added to confluent monolayers 
for 24h and the end-point titer was defined as the first dilution at which Vero cell morphology 
was indistinguishable from untreated wells. Each experiment was performed in duplicate on two 
separate occasions. For measurements of toxin production in vitro, whole cell lysates or culture 
supernatants were separated by SDS-PAGE, transferred to PVDF membrane and toxin B 
detected by Western immunoblot using a specific mouse monoclonal antibody (MA1-7413, 
Thermo Fisher).  
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Fig. S1. Restoration of wild type slpA to the chromosome of FM2.5 and FM2.6. Plasmid 
pRPF233, carrying a wild type copy of the R20291 slpA gene under the control of a tetracycline-
inducible promoter, was introduced into FM2.5 and FM2.6 by conjugation from an E. coli donor 
strain CA434. (A) When grown on solid media, supplemented with thiamphenicol to select for 
the plasmid, both FM2.5/pRPF233 and FM2.6/pRPF233 produced two distinct colony 
morphologies; small colonies that were indistinguishable from those typical of FM2.5 and FM2.6 
and larger colonies that appeared to grow significantly faster than the slpA mutants. (B) When 
the S-layer profile of the larger colonies was analyzed by SDS-PAGE constitutive SlpA 
expression, independent of anhydrotetracycline (ATc) induction, was observed. However, when 
the slpA gene from strain 630 (SLCT-7), which shares 69.4% nucleotide identity with slpAR20291 
(SLCT-4), was introduced expression of SlpA remained inducible. (C) Analysis of these large 
colonies by PCR using one chromosome-specific primer (RF33, annealing 1,250 bp downstream 
of slpA in the secA2 gene) and one plasmid-specific primer (NF1323, annealing in the Ptet 
promoter 122 bp upstream of slpA on pRPF233) confirmed that pRPF233 had integrated into the 
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chromosome at the slpA locus by a single crossover recombination event. Stable slpA revertants, 
FM2.5RW and FM2.6RW, were later generated from these single crossover mutants by culturing 
the bacteria without selection and then screening for plasmid loss and retention of the fast growth 
colony phenotype. 
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1 Ox1424 (ST12) Dingle 003 1 - - - - - - - + + +
2 19108 Citron 053 1 + - - - - - - + + +
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7 Ox2404 (ST16) Dingle 029 2 - + - - - - - - -
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9 CD843 Riley 103 2 - - - + - - - -
Totals (Killed/Tested) 0/1 0/4 2/4 0/4 0/4 0/3 2/4 0/2 0/4 0/4 0/4 0/2
10 Ox1121 (ST35) Dingle 284 3 - - - - - - - - -
Totals (Killed/Tested) 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
11 19103 Citron 001 4 + + +  -  -  -  -  -  -  
12 19135 Citron 001 4 + + + - + - - -
13 LIV24 Lawley 001 4 + + + - + - -
14 BI-9 Lawley 001 4 + + + - + - - -
15 19137 Citron 015 4 + + + - + - - - - -
16 19129 Citron 027 4 + + + -  -  -  -  -  -  
17 19139 Citron 027 4 + + +  -  -  -  -  -  -  
18 19126 Citron 027 4 - + + - + - -  -  -  -  
19 20068 Citron 027 4 - + + - + - -  -  -  -  
20 20315 Citron 027 4 - + +
21 CD196 Lawley 027 4 - + +
22 R20291 Lawley 027 4 - + + - + - - - - - - -
23 Ox160 (ST1) Dingle 027 4 + + - - - - - - -
24 ATCC43255 ATCC 087 4 + + + - + - -
Totals (Killed/Tested) 8/13 14/14 14/14 0/12 8/8 0/12 0/12 0/4 0/8 0/8 0/8 0/1
25 Ox1437a (ST7) Dingle 026 5 - - - - - - - - -
Totals (Killed/Tested) 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
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26 19123 Citron 014 6 - - + + + - - - - - -
27 Ox1896 (ST17) Dingle 018 6 - + + - - - - - -
28 CD4 Fortier 024 6 w - + + + - - - - - -
29 M120 Lawley 078 6H - - + + - - - - - - -
30 8119 Cepheid 078 6H + +
31 8401 Cepheid 078 6H + +
32 8905 Cepheid 078 6H + +
33 10399 Cepheid 078 6H + +
34 10411 Cepheid 078 6H + +
35 Ox575 (ST11) Dingle 078 6H - + + - - - - - -
Totals (Killed/Tested) 0/2 0/4 10/10 10/10 2/3 0/5 0/5 0/5 0/5 0/5 0/5
36 CD630 Lawley 012 7 - - - - - + + - - - - -
37 M68 Lawley 017 7 + - - - + +
38 CF5 Lawley 017 7 + - - - - + + - - -
39 19119 Citron 019 7 + - - - - + + - - -
40 19121 Citron 019 7 + - - - + +
41 19134 Citron 137 7 - - - - + + -
42 Ox1145 (ST4) Dingle 137 7 - - - + + - - - -
Totals (Killed/Tested) 4/6 0/7 0/4 0/7 0/6 7/7 7/7 0/3 0/4 0/4 0/4 0/1
43 Ox1396 (ST54) Dingle 012 8 + - + + - + + + -
Totals (Killed/Tested) 1/1 0/1 1/1 1/1 0/1 1/1 1/1 1/1 0/1
44 19099 Citron 002 9 - - + - - - -
45 19131 Citron 002 9 - + - - -
46 TL178 Lawley 002 9 - - + - - - -
47 Ox1192c (ST8) Dingle 002 9 - - + - - - - - -
48 TL174 Lawley 015 9 + + - - - -
49 19145 Citron 153 9 - - + -  -  -  -  -  -  
Totals (Killed/Tested) 1/5 0/4 0/1 6/6 0/5 0/6 0/6 0/4 0/2 0/2 0/2
50 TL176 Lawley 014 10 - - - - - - - + -
51 19102 Citron 106 10 - - - - - +
52 LIV22 Lawley 106 10 - - - - - - +
53 Ox1533 (ST13) Dingle 129 10 - - - - - - + - -
Totals (Killed/Tested) 0/3 0/2 0/1 0/4 0/3 0/4 0/4 0/3 4/4 0/1 0/1 0/1
54 CD305 Lawley 023 11 - -  -  - +
55 Ox1523 (ST5) Dingle 023 11 - - - - - + - - -
56 19155 Citron 080 11 - - - - - +
Totals (Killed/Tested) 0/2 0/2 0/1 0/2 0/1 0/3 0/3 3/3 0/1 0/1 0/1
57 19146 Citron 010 12 - +
58 CD62 Riley 010 12 - - - - - - - - - + - -
59 CD242 Riley 010 12 - - - - - - - - + -
60 Ox1342 (ST15) Dingle 012 12 - - - - - - - + -
61 F200 Young 12w 12 - - - - +
Totals (Killed/Tested) 0/2 0/3 0/3 0/4 0/3 0/4 0/4 0/3 0/3 5/5 0/3 0/1
62 19142 Citron 046 13 - + - - - - - - - - - -
Totals (Killed/Tested) 0/1 1/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
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Figure S2. C. difficile strain sensitivity patterns to Avidocin-CDs and Diffocin-4. 
Preparations of each Avidocin-CD and Diffocin-4 were serially diluted and spotted on bacterial 
lawns for each strain. If a zone of clearance correlating with killing was detected, the strain was 
deemed sensitive to the agent tested and is demarked by a “+” in the figure. If no zone of 
clearance was observed, the strain was deemed insensitive and is demarked with “-“ in the 
figure. Faint zones of clearance are demarked with a “w”. Not all strains were tested against each 
Avidocin-CD preparation. The number of strains killed per the total number of strains assayed is 
listed for each SLCT. Totals in red indicate less than 100% sensitivity. Boxes highlighted in red 
indicate testing on RBP strain source.  The strain designation, source, ribotype and SLCT are 
listed.  Source designations: Dingle = Kate Dingle, University of Oxford; Riley = Tom Riley, 
University of Western Australia; Lawley = Trevor Lawley, Wellcome Trust Sanger Institute; 
Tenover = Fred Tenover, Cepheid; Young = Vincent Young, University of Michigan; R.M.A.R. 
= R.M. Alden Research Laboratory. 
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Figure S3. Avidocin-CD sensitivity correlates with SLCT. (A) Av-CD291.2 killing efficiency is 
dependent on the level of SLCT-4 SlpA induction. Strain 630 (SLCT-7) or 630 carrying a 
plasmid-borne inducible copy of SLCT-7 SlpA or SLCT-4 SlpA were subcultured to an OD600nm 
 11 
of 0.05, grown for two hours, induced with the indicated concentration of anydrotetracycline 
(ATc) and then challenged with Av-CD291.2 following two hours of induction. Identical 
untreated cultures were included as controls. Shown are means and standard deviations of 
biological duplicates assayed in triplicate. p =<0.01, determined using using two-tailed t-tests 
with Welch's correction. (B) SDS-PAGE analysis of S-layer extracts from 630 (SLCT-7) and a 
panel of eight 630 derivative strains expressing SLCT-1, 2, 4, 6, 7, 8, 10 and 12 under the control 
of a tetracycline-inducible promoter (40). Heterologous SlpA expression was induced with 20 
ng/ml anhydrotetracycline. The positions of the LMW and HMW SLPs, the minor cell wall 
proteins CwpV and Cwp2, and the flagellar subunit FliC are indicated. (C) Spot bioassays with 5 
Avidocin-CDs on the C. difficile strains used in panel B following induction with 
anhydrotetracycline (20 ng/ml). The zone of clearance caused by each Avidocin-CD is shown 
along with the SLCT. 
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Figure S4. Characterization of growth and sporulation. (A) Sporulation of R20291, FM2.5, and 
FM2.5RW over 5 days. Total CFUs and heat-resistant spore CFUs (65°C for 30 min) were 
determined at 24 h intervals. Experiments were carried out in duplicate on biological duplicates. 
Mean and standard deviation are shown. The dotted line indicates the limit of detection. (B) 
Overnight cultures of strains R20291, FM2.5, and FM2.5RW were subcultured to an OD600nm of 
0.05 and growth was monitored hourly for 9 hours by measuring the OD600nm and direct counting 
of CFUs. Shown are the means and standard deviations of biological duplicates with technical 
triplicates. Growth of all 3 strains is identical until an OD600nm of 1.25. FM2.5 prematurely enters 
stationary phase, reaching a maximum OD600nm of 2.2 compared with 3.2 for R20291. (C) 
Sporulation of R20291, FM2.5, and FM2.5RW was monitored by direct counting vegetative cells 
and phase bright spores by phase contrast microscopy at T=0, 48 and 120 of a standard 5 day 
sporulation assay. 20 microscope fields were counted for each strain at each timepoint. The 
number of spores is expressed as a percentage of total with the mean and standard deviations 
shown. * = p<0.01, determined using using two-tailed t-tests with Welch's correction. (D) 
Example microscope fields representative of those counted for panel C. For clarity only 40% of 
each field is shown. In the bottom right image representative spores are marked with red arrow 
heads, a representative vegetative cell with a blue arrow head and representative cell debris with 
green arrow heads. 
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Figure S5. Spore morphology and thermal sensitivity. (A) Electron micrographs of cultures on 
day 5 of the sporulation assay shown in Figure S4A. Spore-containing representative fields are 
shown. Example spores (red arrows) and vegetative cells (blue arrows) are indicated. Higher 
magnification views of individual spores are shown below (boxed in top panels). The core, 
 15 
cortex and coat layers are indicated. (B) Spores were purified on a 20-50% Histodenz gradient 
and CFUs were quantified prior to (Untreated) and following heat stress at 65°C or 75°C for 30 
min. Shown are the mean and standard errors of biological triplicates assayed in triplicate. * = 
p<0.01, determined using using two-tailed t-tests with Welch's correction. (C) Electron 
micrographs of spores used in panel B. The scale bar on each image indicates 2 µm. 
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Figure S6. Bactericidal activity by Avidocin-CD does not result in intracellular toxin release. 
For toxin producing pathogens, antibiotics that lyse bacteria or increase toxin production can 
exacerbate disease severity and lessen the effectiveness of the treatment by inadvertently 
releasing toxins (41). We examined culture supernatants following treatment with Avidocin-CDs 
for the presence of extracellular Toxin B to determine if killing by an Avidocin-CD could result 
in unwanted toxin release. (A) R20291 (RT027) bacteria were incubated for an hour with either 
Av-CD291.2 at the indicated ratio of agent to cells, Av-CD684.1 (which does not kill strain 
R20291) at a 500:1 ratio, or left untreated. After incubation, surviving bacteria (CFU/mL) were 
enumerated. The percentage of CFU following each treatment relative to untreated control is 
shown. The number of spores present in the untreated sample was determined following heat 
treatment at 65 °C for 30 min to kill vegetative cells (lane HK). Av-CD291.2 killing occurred in 
a dose-dependent manner, while Av-CD684.1 treated cells behaved like untreated controls. (B) 
Following Avidocin-CD treatment released toxin B in culture supernatants (ExC) was detected 
by Western immunoblot using a specific monoclonal antibody. As a positive control for toxin 
release, R20291 was treated with a bacteriophage (CD27L) endolysin, which effectively lyses C. 
difficile (42). (C) Following Avidocin-CD treatment, the amount of remaining intracellular toxin 
B was determined by lysing cells with CD27L endolysin and detection by Western immunoblot 
as before (IntC). A fresh sample of untreated R20291 was lysed with CD27L endolysin to show 
 17 
normal intracellular toxin quantities (lane EL). Despite effective killing, intracellular Toxin B 
remained constant with no detectable release observed in the culture supernatants (ExC) at any 
concentration, including samples that exhibited total killing of all vegetative bacterial cells due to 
a large excess (500:1) of Avidocin-CD to bacteria. These results confirm that Avidocin-CDs are 
bactericidal but neither lyse the target cell nor release harmful intracellular stores of toxin B. As 
a result, the use of Avidocin-CD to treat or prevent CDI is unlikely to exacerbate disease 
symptoms. 
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Figure S7. Comparison of C. difficile bacteriophage host range vs. Avidocin-CD sensitivity. 
Preparations of each bacteriophage and corresponding Avidocin-CD were serially diluted and 
spotted on bacterial lawns corresponding to the bacteriophage propagating strains, bacteriophage 
host strains and strains with same SLCT as propagating strain. Bacteriophage plaques are small 
and numerous. Avidocin-CD killing results in a large zone of clearance. Only one host strain, 
denoted in red, had a different SLCT than propagating strain. At high bacteriophage titers, 
bacteriophage are observed to cause “lysis from without” and is denoted by small white arrows. 
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Figure S8. Clustal Omega alignment of SlpA sequences from strains 630 and M68. Identical 
residues are demarked with an asterisk. Residues with strongly similar properties are demarked 
with colon. Residues with weakly similar properties are demarked with a period. An 81.7% 
sequence identity was found between the two SLCT-7 SlpA variants. 
 20 
 
Figure S9. Schematic describing Avidocin-CD construction. (A) The fusion sites used to 
integrate the bacteriophage and prophage genes into the Diffocin-4 gene cluster are shown. There 
is a Bpar fusion site in rtbL as well as alternative downstream fusion sites before or after the 
predicted Diffocin-4 chaperones.  The nucleotide sequences for the fusion region created in each 
Avidocin-CD construct fusion have been deposited in Genbank and given the following 
accession numbers (Table S3). (B) Schematic depicting R-type Bacteriocin and Bacteriophage 
regions for fused BPAR protein. 
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Table S1: Newly identified C. difficile phages. 
 
Phage Source Propagating Strain PtsM-like RBP 
Phi-027b panel of 027 strains 20315 (SLCT-4) Yes 
Phi-123 19123 (SLCT-6) TL176 (SLCT-10) No 
Phi-147 19147 (SLCT-1) 19108 (SLCT-1) Yes 
Phi-242.c1 CD242 (SLCT-12) CD62 (SLCT-12) Yes 
Phi-68.4 M68 (SLCT-7) CF-5 (SLCT-7) Yes 
 
Table S2: Primers used in this study 
 
Primer 
name 
Primer sequence Use 
023-F ATGAAAAAAAGAAATTTAGCA Amplification of slpA variable 
region 
023_010-R CTATAGCTGTTTSTATTCTGTC Amplification of slpA variable 
region 
014+++-F ATGAATAAGAAAARTTTRGCA Amplification of slpA variable 
region 
014_002+-R CTATWGCAGTCTCTATTCTATC Amplification of slpA variable 
region 
RF1 GATCGGATCCTTACATACTTAATAAATC
TTTTAATTTATTTATAACTG 
Cloning of SLCT-4 slpA from 
strain R20291 with RF2 
RF2 GATCGAGCTCTATAATGTTGGGAGGAAT
TTAAGAAATG 
Cloning of SLCT-4 slpA from 
strain R20291 with RF1 
RF6 GATCGGATCCTTACATATCTAATAAATC
TTTTATTTTACTTACAAC 
Cloning of SLCT-H2/6 slpA 
from strain Ox575 with RF2 
RF7 GATCGGATCCCTACATATCTAATAAGTC
TTTTATCTTAGTG 
Cloning of SLCT-10 slpA from 
strain Ox1533 with RF2 
RF8 GATCGGATCCTTACATATCTAATAAATC
TTTTAATTTGCTAACAAC 
Cloning of SLCT-1 slpA from 
strain Ox1424 with RF2 
RF33 GGCTTCTATAGCTTGGTGAA Confirmation of slpA 
recombination with NF1323. 
Chromosome-specific 
RF99 GATCGGATCCTTACATATCTAATAAATC
TTTTATTTTATTTATTACTG 
Cloning of SLCT-6 slpA from 
strain Ox1896 with RF2 
RF101 GATCGGATCCTTATAATTCTAATAAATC
TTTTATTCTCTTAATAAC 
Cloning of SLCT-9 slpA from 
strain Ox1192c with RF134 
RF110 GACATAACTGCAGCACTACTTG Amplification of SLCT-4 slpA 
region containing point 
mutations and watermark 
RF111 CAGGATTAACAGTATTAGCTTCTGC Amplification of SLCT-4 slpA 
region containing point 
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mutations and watermark 
RF132 GATCGGATCCTTACATATTTAATAAATC
TTTAAGCTTAGTTAC 
Cloning of SLCT-8 slpA from 
strain Ox1396 with RF2 
RF133 GATCGGATCCTTACATTCCTAATAAATC
TTTTAATTTATTAATAAC 
Cloning of SLCT-12 slpA from 
strain Ox1342 with RF134 
RF134 GATCGAGCTCTATAATGTTGGGAGGAAT
TTAAGGAATG 
Cloning of SLCT-9 and 12 
slpA with RF101 and RF133 
respectively 
RF135 CAGGTTGATAATAAATTAGACAATTTAG
GTGATGG 
Introduction of slpA 
watermark with RF136 
RF136 TGTAAACAATAATTTACTTGCATCTTCT
G 
Introduction of slpA 
watermark with RF135 
RF231 GATCGGATCCTTACATATCTAATAAATC
TTTCATTTTGCTTATTAC 
Cloning of SLCT-2 slpA from 
strain Ox858 with RF2 
NF1323 CTGGACTTCATGAAAAACTAAAAAAAA
TATTG 
Confirmation of slpA 
recombination with RF33. 
Plasmid-specific 
NF1414 GATCGAGCTCTATAATGTTGGGAGGAAT
TTAAGAAATG 
Cloning of SLCT-7 slpA from 
strain 630 with NF1415 
NF1415 GATCGGATCCTTACATATCTAATAAATC
TTTCATTTTG 
Cloning of SLCT-7 slpA from 
strain 630 with NF1414 
 
Table S3: Genbank accession identifiers. 
   
Construct Source Accession Id: 
Diffocin-4 CD4 KX557294 
Av-CD291.2 R20291 genome KX592438 
Av-CD027.2 Phi-027b KX592434 
Av-CD681.1 M68 genome KX592441 
Av-CD682.1 M68 genome KX592442 
Av-CD684.1 M68 genome/phi-M68.4 KX592443 
Av-CD685.1 M68 genome KX592444 
Av-CD305.1 CD305 genome KX592439 
Av-CD123.2 Phi-123 KX592435 
Av-CD242.2 Phi-242.c1 KX592437 
Av-CD147.1 Phi-147 KX592436 
Av-CD630.1 630 genome KX592440 
 
